Pulmonary vascular disease & thromboembolism

1. J Am Coll Cardiol19 Feb 2026

   2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

   Guideline or statement

2. Circulation19 Feb 2026

   2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

   Guideline or statement

3. ESC Heart Fail17 Feb 2026

   Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up

   Cohort study

4. Circulation12 Feb 2026

   Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design

   Cohort study

5. ESC Heart Fail10 Feb 2026

   Evaluation of LCN2 and miR-8078 as diagnostic biomarkers for congenital heart disease-associated pulmonary arterial hypertension

   Diagnostic or prognostic study

6. Eur Heart J6 Feb 2026

   Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up

   Cohort study

7. Am Heart J3 Feb 2026

   Reperfusion strategies for acute pulmonary embolism: Design and rationale of RECONNECT-PE—A living systematic review and meta-analysis

   Trial design

8. JAMA3 Feb 2026

   Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis

   Cohort study

9. Eur Heart J Acute Cardiovasc Care30 Jan 2026

   Effect of large bore mechanical thrombectomy on pulmonary vascular resistance in patients with acute pulmonary embolism

   Cohort study

10. Eur Heart J Qual Care Clin Outcomes19 Jan 2026

    Impact of catheter-directed thrombolysis on the socio-economic burden of pulmonary embolism in Germany: a cost-effectiveness analysis

    Meta-analysis

11. Nat Med9 Jan 2026

    The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension

    Diagnostic or prognostic study

12. ESC Heart Fail8 Jan 2026

    Agreement of thermodilution and direct Fick methods for cardiac output across varying haemodynamic conditions

    Cohort study

13. JACC Cardiovasc Imaging5 Jan 2026

    The Prognostic Value of 18F-FAPI PET/CT Imaging in Pulmonary Arterial Hypertension

    Cohort study

14. Eur Heart J12 Dec 2025

    Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers

    Secondary analysis

15. Eur J Prev Cardiol22 Nov 2025

    Arterial cardiovascular disease risk after venous thromboembolism in young adults: a Danish nationwide cohort study

    Cohort study

16. BMJ12 Nov 2025

    Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation

    Research article

17. Lancet8 Nov 2025

    Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials

    Randomised controlled trial

18. Circulation3 Nov 2025

    Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial

    Randomised controlled trial

19. JACC Heart Fail31 Oct 2025

    A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension

    Diagnostic or prognostic study

20. N Engl J Med30 Sep 2025

    Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

    Randomised controlled trial

21. J Am Coll Cardiol30 Sep 2025

    Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension: A Registry Report and Updated Meta-Analysis

    Meta-analysis

22. N Engl J Med30 Aug 2025

    Apixaban for Extended Treatment of Provoked Venous Thromboembolism

    Randomised controlled trial

23. Eur Heart J29 Aug 2025

    Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension

    Research article

24. Eur J Heart Fail7 Aug 2025

    Exercise Haemodynamics in Pulmonary Hypertension – a Prospective Pressure–Volume Loop Study on Right Ventricular Adaptation and Prognosis

    Cohort study

25. Eur Heart J22 Jun 2025

    Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis

    Meta-analysis

26. J Am Coll Cardiol17 Jun 2025

    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of an International Multicenter Prospective Registry

    Cohort study

27. Eur J Prev Cardiol14 May 2025

    Burden and long-term impact of pulmonary embolism on health-related quality of life: a matched cohort study

    Cohort study

28. Circulation13 May 2025

    Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research: A Scientific Statement From the American Heart Association

    Guideline or statement

29. JAMA22 Apr 2025

    Population-Scale Studies of Protein S Abnormalities and Thrombosis

    Cross-sectional study

30. Eur Heart J2 Apr 2025

    Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015–22): sex differences and shifts during the coronavirus disease 2019 pandemic

    Cohort study

31. N Engl J Med31 Mar 2025

    Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death

    Randomised controlled trial

32. N Engl J Med29 Mar 2025

    Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

    Randomised controlled trial

33. Circulation20 Mar 2025

    Disparities in Current Pulmonary Embolism Management and Outcomes: A Scientific Statement From the American Heart Association

    Guideline or statement

34. JACC Heart Fail5 Mar 2025

    Global Burden of Pulmonary Arterial Hypertension and Associated Heart Failure: Global Burden of Disease 2021 Analysis

    Secondary analysis

35. Lancet1 Mar 2025

    Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

    Randomised controlled trial

36. Circulation28 Jan 2025

    Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial

    Randomised controlled trial

37. Eur J Prev Cardiol25 Jan 2025

    One-minute sit-to-stand test cut-offs for risk stratification based on six-minute walk test thresholds in pulmonary hypertension

    Diagnostic or prognostic study

38. JAMA24 Dec 2024

    Postmarketing Surveillance of Inferior Vena Cava Filters Among US Medicare Beneficiaries: The SAFE-IVC Study

    Cohort study

39. Circulation18 Nov 2024

    Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)

    Randomised controlled trial

40. Eur Heart J18 Nov 2024

    Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study

    Cohort study

All 122 Briefs in ExploreShowing Briefs 41–80 of 122, newest first